The first three common De-Da-Botu monoclonal antibody has been approved in Japan for the treatment of breast cancer.
On December 28th, Jin10 Data reported that on December 27th, Daiichi Sankyo announced that the targeted TROP2 antibody conjugate drug (ADC) DATROWAY® (decarbazine monoclonal antibody), jointly developed by the company and AstraZeneca, has been approved in Japan for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative (IHC 0, IHC 1+ or IHC treated with chemotherapy.